Research programme: ASIC and NGF/p75 antagonists - PainCeptor

Drug Profile

Research programme: ASIC and NGF/p75 antagonists - PainCeptor

Alternative Names: PPC-1807; PPC-5383; PPC-5692; PPC-778

Latest Information Update: 25 Oct 2011

Price : $50

At a glance

  • Originator PainCeptor Pharma Corporation
  • Class Small molecules
  • Mechanism of Action ASIC channel antagonists; Nerve growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Pain

Most Recent Events

  • 31 Dec 2009 Discontinued - Preclinical for Pain in Canada (unspecified route)
  • 15 Sep 2008 Preclinical development is ongoing
  • 24 Nov 2006 Preclinical data have been added to the adverse events and pharmacokinetics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top